COVID-19-Induced Hyperleucocytosis in Chronic Lymphocytic Leukaemia. Academic Article uri icon

Overview

abstract

  • UNLABELLED: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for the current global pandemic, coronavirus disease 2019 (COVID-19). COVID-19 usually presents with respiratory symptoms but can affect multiple organ systems. A wide spectrum of complications can occur depending upon the comorbidities of patients. There is limited literature available regarding the presentation and outcome of COVID-19 in chronic lymphocytic leukaemia (CLL) patients. We report 2 cases of COVID-19-induced hyperleucocytosis (WBC count >100,000/μl) in CLL patients. LEARNING POINTS: Lymphopenia has been associated with severe disease and is a poor prognostic factor in COVID-19 infected patients; however, our cases show COVID-19-induced hyperleucocytosis (WBC count >100,000/μl)/lymphocytosis in CLL patients.Prior reports suggest that ibrutinib may have a protective effect against COVID-19 by decreasing inflammation and preventing progression to ARDS.

publication date

  • March 15, 2021

Identity

PubMed Central ID

  • PMC8046275

Digital Object Identifier (DOI)

  • 10.1002/jha2.98.

PubMed ID

  • 33869094

Additional Document Info

volume

  • 8

issue

  • 3